New combo therapy offers hope for head and neck cancer patients who Can't take standard chemo

NCT ID NCT04858269

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 6 times

Summary

This phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen shrinks tumors more effectively than pembrolizumab alone. Researchers are also tracking overall survival and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab, Carboplatin, Paclitaxel
What this could lead to
If successful, this weekly regimen could offer a more tolerable and effective first-line treatment option for patients with metastatic head/neck cancer who cannot use standard 5FU chemotherapy.
What could go wrong
This is a small phase 2 study with only 31 participants, so results may not apply broadly. The combination may cause side effects like low blood counts or immune-related reactions, and it may not improve survival compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wake Forest Baptist Health Sciences

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.